[HTML][HTML] Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit
F Brites, M Martin, I Guillas, A Kontush - BBA clinical, 2017 - Elsevier
Uptake of low-density lipoprotein (LDL) particles by macrophages represents a key step in
the development of atherosclerotic plaques, leading to the foam cell formation. Chemical …
the development of atherosclerotic plaques, leading to the foam cell formation. Chemical …
Modulation of paraoxonase (PON1) activity
LG Costa, A Vitalone, TB Cole, CE Furlong - Biochemical pharmacology, 2005 - Elsevier
Paraoxonase 1 (PON1) is a serum enzyme closely associated with high density lipoprotein
(HDL). PON1 hydrolyzes several organophosphorus compounds used as insecticides, as …
(HDL). PON1 hydrolyzes several organophosphorus compounds used as insecticides, as …
The three-gene paraoxonase family: physiologic roles, actions and regulation
LP Précourt, D Amre, MC Denis, JC Lavoie, E Delvin… - Atherosclerosis, 2011 - Elsevier
The paraoxonase (PON) gene family is composed of three members (PON1, PON2, PON3)
that share considerable structural homology and are located adjacently on chromosome 7 in …
that share considerable structural homology and are located adjacently on chromosome 7 in …
Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1
SP Deakin, RW James - Clinical Science, 2004 - portlandpress.com
PON1 (paraoxonase-1) is an HDL (high-density lipoprotein)-associated enzyme capable of
hydrolysing diverse substrates from OP (organophosphate) toxins to oxidized phospholipids …
hydrolysing diverse substrates from OP (organophosphate) toxins to oxidized phospholipids …
Fenofibrate: a review of its use in dyslipidaemia
K McKeage, GM Keating - Drugs, 2011 - Springer
Fenofibrate is a fibric acid derivative indicated for the treatment of severe
hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to …
hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to …
Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus
GM Keating, KF Croom - Drugs, 2007 - Springer
Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary
hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have …
hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have …
Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy
W Annema, A von Eckardstein - Translational Research, 2016 - Elsevier
Low plasma levels of high-density lipoprotein (HDL) cholesterol are associated with
increased risks of coronary heart disease. HDL mediates cholesterol efflux from …
increased risks of coronary heart disease. HDL mediates cholesterol efflux from …
Variation in paraoxonase-1 activity and atherosclerosis
Variation in paraoxonase-1 activity and atherosclerosis : Current Opinion in Lipidology
Variation in paraoxonase-1 activity and atherosclerosis : Current Opinion in Lipidology Log in or …
Variation in paraoxonase-1 activity and atherosclerosis : Current Opinion in Lipidology Log in or …
The human paraoxonase gene cluster as a target in the treatment of atherosclerosis
ZG She, HZ Chen, Y Yan, H Li, DP Liu - Antioxidants & redox …, 2012 - liebertpub.com
The paraoxonase (PON) gene cluster contains three adjacent gene members, PON1, PON2,
and PON3. Originating from the same fungus lactonase precursor, all of the three PON …
and PON3. Originating from the same fungus lactonase precursor, all of the three PON …
[HTML][HTML] Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia
Abstract Human serum paraoxonase 1 (PON1) is an enzyme with esterase activity, and is
physically bound to high-density lipoproteins (HDL). It plays a key role in the action of HDL …
physically bound to high-density lipoproteins (HDL). It plays a key role in the action of HDL …